Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Anticancer activities of novel Mannich bases against prostate cancer cells

Journal Article · · Medicinal Chemistry Research (Print)
 [1];  [2]
  1. Giresun University, Vocational High School of Health Services, Department of Medical Services and Techniques (Turkey)
  2. Karadeniz Technical University, Department of Chemistry (Turkey)

This study was designed to synthesize hybridizing molecules starting from compound of 6-(4-phenyl-piperazin-1-yl)pyridine-3-ylamine by enhancing its biological activity with other heterocycles and to determine anticancer activity of the resulting compounds. To this end, 6-(4-phenylpiperazin-1-yl)pyridin-3-ylamine (4) was used as the leading compound, which is known to exert anticancer activities. The synthesis of the leading compound was carried out using 1-(5-nitropyridin-2-yl)-4-phenylpiperazine (3) which was obtained by a novel method with the reaction of N-phenylpiperazine (2) and 2-chloro-5-nitropyridine. 6-(4-phenylpiperazin-1-yl)pyridin-3-ylamine (4) was converted to compound 5, an active intermediate compound, by substitution of one of the amine hydrogens with ethyl bromoacetate. The resulting ester product (5) followed by the hydrazidation (6) was added arylisocyanate to obtain the active intermediate (8). Then, by a series of substitution through cyclization and condensation reactions, thiazolidinone (9), 1,3,4-oxadiazole (7), and 1,2,4-triazole (10) were synthesized. Novel Mannich bases (11a–11f and 12a–12f) were obtained using oxazole (7) and triazole (10) hetero rings with primer or secondary amine compounds. The characterization of the compounds was completed using FT IR, {sup 1}H-NMR, {sup 13}C-NMR, HRMS spectroscopic methods and elemental analysis technique. The chemicals, then, were tested for their anticancer activities against prostate cancer cell lines PC3 [ATCC, CRL-1435], LNCaP [ATCC, CRL-1740], and DU145 [ATCC, HTB-81]. The results revealed that the Mannich bases exhibited moderate cytotoxic activity against cancer cells tested.

OSTI ID:
22936162
Journal Information:
Medicinal Chemistry Research (Print), Journal Name: Medicinal Chemistry Research (Print) Journal Issue: 11 Vol. 28; ISSN 1054-2523
Country of Publication:
United States
Language:
English

Similar Records

Synthesis and anticancer effects of α-lipoic ester of alloxanthoxyletin
Journal Article · Wed May 01 00:00:00 EDT 2019 · Medicinal Chemistry Research (Print) · OSTI ID:22936192

Spectral Analysis of 3-(Adamantan-1-yl)-4-Ethyl-1-[(4-Phenylpiperazin-1-yl) Methyl]-1H-1,2,4-Triazole-5(4H)-Thione
Journal Article · Tue May 15 00:00:00 EDT 2018 · Journal of Applied Spectroscopy · OSTI ID:22810099

Phenolic-containing mannich base reaction products and fuel compositions containing same
Patent · Mon Feb 20 23:00:00 EST 1989 · OSTI ID:6058391